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Abstract  
Background & Aims: T cells mediate the development of inflammation in inflammatory 
bowel disease (IBD). We investigated the effects of an antibody against CD3 called 
otelixizumab, which induces immune tolerance, in intestinal mucosa samples from 
patients. Methods: Intestinal tissues were isolated from individuals undergoing routine 
endoscopy or from patients undergoing intestinal surgery for colon cancer or IBD; 
healthy surrounding tissues were collected as controls. Isolated lamina propria 
mononuclear cells (LPMC) and mucosal tissue explants were incubated with 
otelixizumab for 24 or 48 hours. Production of inflammatory cytokines was determined 
by ELISA. Levels of 36 cytokines and chemokines and phosphorylation of 39 receptor 
tyrosine kinases and signaling molecules were measured using protein arrays. 
Immunoblot analysis was used to analyze T-cell transcription factors. Results: 
Incubation of intestinal tissues or LPMC with otelixizumab reduced production of 
interferon γ, interleukin (IL)17A, and other inflammatory cytokines and chemokines, 
simultaneously increasing production of IL10. Mucosal biopsies from patients with IBD 
retained inflammation-associated tyrosine phospho-protein profiles ex vivo. Incubation 
of the inflamed tissue with otelixizumab reduced phosphorylation of these proteins to 
levels observed in control tissues. Otelixizumab also markedly reduced phosphorylation 
of proteins associated with T-cell receptor activation. Neutralization of IL10 blocked the 
anti-inflammatory effects of otelixizumab. Conclusions: We observed anti-inflammatory 
effects of anti-CD3 in inflamed intestinal tissues from patients with IBD. The antibody 
appears to downregulate T-cell activation via IL10. 
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Introduction  
Since the first anti-CD3 antibody, muromonab (OKT3), was developed more than 
30 years ago to prevent transplant rejection and graft versus host disease 
1
, 
considerable progress has been made in the development and engineering of anti-CD3 
antibodies for the treatment of immune disorders. OKT3 induces a cytokine storm, 
which obviates its use in the treatment of autoimmune conditions 
2-4
. This cytokine 
storm is a consequence of the cross-linking of the CD3/T cell receptor (TcR) on T cells, 
coupled with Fc binding to the Fc gamma Receptor (FcR) on other immune cells. To 
reduce toxicity of anti-CD3 antibodies, F(ab)2 fragments 
5
 and mutated, humanized Abs, 
which did not bind FcR, have been developed 
6
.  It is thought that these tolerising anti-
CD3 antibodies function by driving the internalization of the TcR/CD3 complex so that 
signaling via peptide/MHC is abolished
7, 8
. In addition, the antibodies when binding to 
CD3/TcR may signal to the cell and drive differentiation along a tolerogenic pathway 
7
.  
Finally, there is some evidence that tolerising anti-T cell antibodies can cause T cell 
apoptosis
9
. 
Tissue injury in inflammatory bowel disease is driven by T cells 
10 
and is therefore 
a disease target for T cell therapies. Initial studies in ulcerative colitis (UC) with the anti-
CD3 antibody visilizumab showed clinical benefit 
11, 12
, however, a randomized, placebo-
controlled trial gave negative results 
13
. In Crohn’s disease (CD), a phase I study of the 
anti-CD3 antibody NI-0401 showed no improvement in Crohn’s disease activity index, 
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but there was significant endoscopic improvement
14
.  Further clinical studies are clearly 
needed, however, what remains lacking is any evidence that anti-CD3 antibodies have 
an effect on pro-inflammatory T cells in the mucosa of patients with IBD. 
Otelixizumab (TRX4 or ChAglyCD3), is an Fc-engineered, chimeric/humanized 
monoclonal IgG1 antibody against human CD3-epsilon which showed promising early 
results in Type I diabetes
15, 16
 but  was not superior to placebo in Phase 3 studies when 
given at a lower dose than the earlier work 
17
.  We have developed ex vivo assays where 
T cell activity in inflamed bowel tissue can be accurately studied
18-20
 , and so we have 
investigated for the first time if anti-CD3 antibodies change T cell function in human 
tissues. 
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Materials and Methods 
 
Reagents and Antibodies 
All reagents were purchased from Sigma Aldrich (Gillingham, UK) unless 
otherwise stated. Anti-human CD28 was purchased from R&D systems (Abingdon, UK). 
Otelixizumab (Tolerx, Cambridge, MA, USA) is an aglycosylated chimeric/humanized 
monoclonal antibody (IgG1 lambda) directed against human CD3/epsilon (generously 
provided by GlaxoSmithKline). YTH12.5 is a mitogenic rat anti-human CD3 antibody 
(IgG2b lambda; provided by Tolerx) and the parental Ab of otelixizumab. Purified human 
IgG1 lambda was used for control purposes (Sigma Aldrich). IL-10 was neutralized with 
rat anti-IL-10 (used at 10μg/ml; BioLegend, Cambridge, UK).  
Patient samples 
Tissue was obtained during routine endoscopy or from surgical specimens of 
patients undergoing intestinal surgery because of colon cancer or IBD. Healthy intestinal 
tissue surrounding malignant tumors was sampled and used as control. All patients took 
part in this study after informed written consent. The study was approved by the local 
ethics committee. Patient characteristics are listed in supplementary table SI. 
Isolation of peripheral blood mononuclear cells 
Peripheral blood was obtained from healthy volunteers after informed consent, 
diluted with PBS 1:1 and layered on top of Ficoll Paque solution (GE Healthcare, 
Amersham, UK). After centrifugation at 21˚C for 30min, 300g without break, the buffy 
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coat was aspirated and washed once in PBS. Cells were cultured in RPMI/ 10% human 
serum/ Pen/Strep/ L-Glutamine or subjected to immunostaining.  
Processing of tissue specimens 
With surgical specimens, the mucosa was cut off the submucosa and cut into 
2mm
2
-sized pieces. Epithelial cells of biopsies or mucosal pieces were removed with 1 
mM EDTA in HBSS containing 100 U/ml penicillin and 100 μg/ml streptomycin 
(Pen/Strep) for 30min. A single cell suspension was prepared in RPMI/ 10% FBS/ L-
Glutamine/ Pen/Strep/ 50μg/ml gentamicin/ 5μg/ml amphotericin B with collagenase D 
(1mg/ml) and DNase (10U/ml; Roche, Burgess Hill, UK) for 1h. Cells were passed through 
a cell strainer and subjected to density centrifugation with Ficoll Paque (GE Healthcare, 
Amersham, UK) by layering the cell suspension on top of the Ficoll. After centrifugation 
at 21˚C for 30min, 300g without break, the buffy coat was aspirated and washed once in 
PBS. Cells were cultured in RPMI/ 10% human serum/ Pen/Strep/ L-Glutamine. 
Organ culture of mucosal explants 
The mucosa of intestinal surgical specimens was cut into 3mm
2
 pieces and 
cultured in 24-well plates in 300μl serum-free HL1-medium (Lonza, Cambridge, UK) 
containing glutamine, Pen/Strep, and 50μg/ml gentamicin. Mucosal samples were 
emerged in liquid and culture was performed for up to 48h at 37°C, 5% CO2. For 
antibody experiments, the respective antibody was added to the culture medium. 
Supernatants and tissue samples were snap-frozen and stored at -70C.  
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Flow cytometry 
 Antibodies were used at the concentrations recommended by the manufacturer: 
anti-CD4-FITC; anti-CD25-PE, CD2-APC, IFN-γ-PECy7, IL-10-PE, and matched isotype 
controls (BD Bioscience, Oxford, UK). PBS/20% human serum was used to block non-
specific binding and cell surface staining was performed for 30min on ice. For 
intracellular cytokine staining, cells were cultured overnight with otelixizumab or human 
IgG. For the last 4h of culture, 2 mM monensin was added. After surface staining, cells 
were fixed in Leucoperm (AbD Serotec, Oxford, UK) solution A, followed by 
permeabilization in solution B and intracellularly stained for 30min. Intracellular staining 
of Foxp3 was performed with the Alexa Fluor 647 anti-human Foxp3 flow kit from 
BioLegend (London, UK). Cell viability was assessed by annexin V-FITC and propidium 
iodide (PI) staining (BD Bioscience) as previously described 
21
. For multi-colour flow 
cytometry, all analyses included the appropriate fluorescence-minus-one controls (i.e. 
samples stained with every reagent except for the one of interest to guide 
compensation. Flow cytometry was performed using the LSRII analyzer (Becton 
Dickinson), data were analyzed with FACS Diva software. 
Quantification of CD3/TCR modulation by flow cytometry 
PBMC (1x10
6
/mL) were cultured in RPMI + 10% AB serum in the presence or absence of 
otelixizumab. At indicated time points cells were removed, washed with FACS buffer 
(PBS + 1% FCS + sodium azide 0.1%) After Fc blocking for 5min with TruStain FcX 
(BioLegend) cells were stained with: CD4-PerCP-Cy5.5(clone RPA-T4), CD8-APC (clone 
RPA-T8), CD3-FITC(clone SK7), TCRab-PE (clone IP26) or anti-Human IgG Fc-PE (clone 
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HP6017) (all BioLegend). After washing with 3ml FACS buffer the cells were re-
suspended in 300μl Cytofix (BD Biosciences). Lymphocytes were gated on FSC v SSC and 
50,000 events were acquired. The Mean Fluorescence Intensity (MFI) data for PE and 
FITC fluorescence for gated CD4 and CD8 cells were converted to Molecules of 
Equivalent Soluble Fluorochrome (MESF) values using Quantum Simply Cellular beads 
(Bangs Laboratories) as per the manufacturer’s instructions. 
Western blotting 
 Whole cell lysates were subjected to SDS-PAGE and immunoblotting as 
previously described 
21
. Anti-T-bet (Santa Cruz, Heidelberg, Germany), anti-RORgt and 
anti-β-actin (Abcam, Cambridge, UK) were used according to manufacturer’s 
instructions. Intensities of the protein bands were measured using Image J software and 
relative values were calculated by dividing the IgG and otelixizumab values by the 
untreated control. 
Signaling arrays and cytokine arrays 
 Phosphorylation status of receptor tyrosine kinases and signaling molecules was 
determined by employing PathScan RTK signaling arrays (Cell Signaling, Danvers, MA, 
USA). Seventy-five μg protein of whole cell lysates were probed onto the array. Cytokine 
arrays were purchased from R&D Systems (“Proteome Profiler Cytokine array kit, Panel 
A”) and performed with 100 μl of supernatants according to instructions. The 
chemiluminescent signals of all arrays were detected on X-ray films and the pixel 
intensities measured using ImageJ software. Heatmaps of relative pixel intensities were 
generated with R (v. 2.15.0) and the compdiagTools package (v. 1.8.2) 
22, 23
 . For 
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consistency and easier data presentation, the intensity values >1700 were given the 
same dark red colour. When otelixizumab reduced cytokines to undetectable levels, the 
fold reduction was given an arbitrary value of 10. 
ELISA 
Cytokine concentrations in culture supernatants were determined by enzyme 
linked immunosorbent assay (ELISA) using kits from R&D Systems (IL-17A), ImmunoTools 
(Friesoythe, Germany; IFN-γ) and ebioscience (Hatfield, UK; IL-2) according to 
manufacturer’s instructions. 
Quantitative real-time PCR 
Tissue was sonicated in Trizol reagent (Life Technologies, Paisley, UK) and RNA 
isolated with the Direct-Zol kit (Zymo Research, Irvine, CA, USA).  Reverse transcription 
was performed using QuantiTect Reverse Transcription Kit (Qiagen, Manchester, UK). 
Quantitative RT- PCR was performed using QuantiFast SYBR Green PCR Kit (Qiagen) on a 
7500 Real-Time PCR System (Applied Biosystems, Paisley, UK). IL-10 expression was 
determined as the geometric mean of IL10 normalized to GAPDH, RPL30 and PGK1 using 
the 2
-ΔCt
 method 
24
. Primers: IL10 (QT00041685), PGK1 (QT00013776), RPL30 
(QT00056651) (Qiagen). GAPDH: (forward) TGCACCACCAACTGCTTAGC; (reverse) 
GCATGGACTGTGGTCATGAG. 
Statistical testing 
  Statistical analysis was performed with GraphPad Prism or InStat software. Two-
tailed Student t-test was used to compare two independent values and the One-way 
ANOVA with post-test was used for multiple comparisons. Array data were statistically 
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analysed by calculating the average of all individual proteins in the individual groups and 
the sums of the resulting two data sets were then compared to each other with the 
Wilcoxon rank-sum test (in GraphPad Prism). For example, the intensity values of the 
individual cytokines in the group “CD treated with IgG” were averaged and the whole 
set of values then statistically compared to all cytokine averages in group “CD treated 
with otelixizumab”. Tables used for calculations are shown in the supplementary 
material. A p value < 0.05 was considered significant. 
 
Results 
Otelixizumab dramatically reduces surface CD3 in blood and mucosal T cells. 
We aimed to use concentrations of otelixizumab which caused internalization of surface 
CD3. With one million blood T cells, a concentration of 1μg/ml otelixizumab reduced 
CD3 sites from around 200,000 per cell to < 5,000 (Fig 1A). This effect persisted for 24h. 
Otelixizumab caused the internalization of surface CD3 as well as disappearance of the 
αβ T cell receptor from the cell surface. Otelixizumab bound to CD3 blocked the binding 
of all available anti-TCR and anti-CD3 detection antibodies we have tested. As a 
consequence down-modulation of the CD3/TCR complex could only be measured by 
detection of bound otelixizumab with secondary detection antibodies. Down-
modulation was evident after 4h (data not shown) and by 24h less than 50% of CD3/TCR 
molecules remained (Fig 1A). By day 4 almost 90% of the complexes had been 
internalized (data not shown). When biopsies from UC patients were cultured with 
1µg/ml otelixizumab for 16h, rapidly dispersed without collagenase treatment between 
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two glass slides and incubated with FITC-anti-CD3, CD3 expression was greatly reduced 
on the cells from biopsies treated with otelixizumab. Strong CD3 expression was 
observed in cells isolated from biopsies treated with a control IgG (Fig 1B). 
 
 
Otelixizumab is non-mitogenic and does not affect cell viability 
T cells in both normal and inflamed human gut are in an activated state 10, 
therefore the first experiments were designed to ensure that otelixizumab was neither 
mitogenic nor increased pro-inflammatory cytokine production by normal and IBD 
lamina propria mononuclear cells (LPMC). The rat YTH12.5 antibody, from which 
otelixizumab was derived, induced proliferation of T cells from normal human gut and 
from IBD mucosa. In contrast, otelixizumab was non-mitogenic, even in the presence of 
anti-CD28 (Fig 1C). In terms of cytokine production, YTH12.5 induced high levels of IFN-γ 
and IL-17A, both being important cytokines in IBD
25
, by both normal and IBD LPMC. 
While there was some spontaneous IFN-γ and IL-17A production by IBD LPMC, cytokine 
production was reduced by otelixizumab (Fig 1D). Crohn’s disease and control LPMCs 
were next cultured with plate-bound anti-CD3 Ab and anti-CD28 Ab in the culture 
medium. When otelixizumab was added at the onset of the cultures, IFN-γ and IL-17A 
production were significantly reduced. We also added otelixizumab after 16h to 
αCD3/CD28 stimulated LPMC. IFN-γ and IL-17A concentrations were reduced, but 
significance was only reached for control LPMCs (Fig 1E). To test if otelixizumab 
treatment can reduce the stimulatory capacity of a subsequent YTH12.5 treatment, we 
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cultured LPMCs from normal and inflamed mucosa for 3h with otelixizumab, changed 
the medium, then added YTH12.5 for 21h. Pre-treatment with otelixizumab before 
YTH12.5 was added strongly diminished IFN- γ production by LPMCs. We observed that 
LPMCs pre-treated with YTH for 3h, then cultured with otelixizumab show a reduced 
IFN- γ response (Fig 1E, for IL-17A and IL-2 data see supplementary figure S1). 
We determined if the inhibitory effects of otelixizumab were due to T cell death 
since an earlier in vitro study had indicated that the anti-CD3 antibody visilizumab 
rapidly induced apoptosis in gut T cells in IBD 
9
. LPMCs were cultured with otelixizumab 
for 48h and stained with annexin V and propidium iodide. Otelixizumab at 
concentrations of up to 10μg/ml did not increase the number of apoptotic or dead cells 
in LPMCs from healthy gut or from CD and UC mucosa (Fig 1F). Crohn’s disease and UC 
LPMCs were more resistant to cell death than cells from healthy colon, confirming a 
previous study 
26
.  
 
 
Otelixizumab decreases proinflammatory cytokine production in inflamed mucosa 
We next examined T cell responses in CD and UC mucosal biopsies cultured ex 
vivo. Otelixizumab reduced the concentrations of IFN-γ and IL-17A in CD and UC explant 
culture supernatants compared to the IgG control (Fig 2A). The transcription factors T-
bet and RORγT, the main regulators of IFN-γ and IL17 expression, respectively, were also 
reduced in CD explants treated with otelixizumab (Fig 2B). Supernatants of inflamed CD 
and UC explants were further subjected to a protein array to measures relative levels of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
13
36 cytokines and chemokines (Fig 2C, D, E). Otelixizumab in CD and UC organ cultures 
had strong global effects. For Crohn’s disease there was a 2-5 fold decrease in C5a, 
sCD40L, G-CSF, GRO-α, ICAM-1, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-12, IL-13, IL-16, IL-
27, CXCL11, CCL2, CCL3, TNF-α, RANTES, CCL4, sTREM-1, and a 5-10 fold decrease in 
GM-CSF, CCL-1, IL-6, IL-17A, IL-23, IL-32α, CXCL10, CXCL12. For ulcerative colitis there 
was a 2-5 fold decrease in C5a, ICAM-1, IFN-γ, IL-12, IL-13, IL-27, CXCL11, CCL2, CCL3, 
CCL4, RANTES, a 5-10 fold decrease in GM-CSF, IL-1β, IL-2, IL-4, IL-5, IL-17A, IL-32α, 
CXCL10, CXCL12, and  sTREM-1, and a greater than ten-fold decrease in TNF-α and IL-1α. 
Cytokines which changed less than two-fold were IL-1RA, IL-8, MIF, and Serpin E1, in CD, 
and sCD40L, G-CSF, GRO-α, IL-1RA, IL-16, IL-8, IL-23, MIF, and Serpin E1 in UC. The 
average value of all cytokines of IgG-treated vs. otelixizumab-treated samples were 
significantly different for CD as well as for UC (Figures 2C, D showing representative 
cases). IgG (green bars), otelixizumab (red bars). Fig 2E shows heatmaps of all 12 cases. 
The individual values are listed in supplementary table SII and III. Otelixizumab 
significantly increased the levels of IL-10 in IBD mucosa supernatants (supplementary 
tables II and III).  
 
Otelixizumab reduces phosphorylation in IBD tissue to levels observed in healthy 
mucosa 
Because phosphorylation of receptors and signaling molecules is an important 
mechanism for cells to respond to inflammation and other extracellular stimuli, we 
analysed the phosphorylation status of 39 receptor tyrosine kinases and signaling 
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molecules in freshly isolated colonic mucosa of healthy individuals and IBD patients by 
employing a phosphorylation-specific protein array. Molecules on the array included 
growth factor receptors, Ephrin family members, ERK, Zap70, Lck, Src, and Stat1 and 
Stat3. Very few phosphorylation events were detectable in lysates of freshly isolated 
healthy colonic mucosa (Fig 3A, single representative cases). In contrast, inflamed CD 
mucosa and UC mucosa showed high relative intensity of phosphorylation of the 
majority of analysed kinases (Fig 3A, B). There was variation between individual 
patients, especially in Crohn’s disease, probably reflecting the patchy nature of the 
lesions. Average intensity values of phospho-proteins of IgG-treated vs. otelixizumab-
treated samples were significantly different for CD and UC.  
When phosphorylation status was measured in lysates of CD mucosal explants 
cultured with IgG for 48h, the strong level of phosphorylation was maintained, 
indicating the continuing persistence of the inflammatory process ex vivo (Fig 3C 
showing single representative cases). Addition of otelixizumab to CD explants for 48h 
strongly reduced the phosphorylation of the majority of kinases (green bars in Fig 3C). 
Similar results were observed for UC explants cultured with IgG or otelixizumab for 48h 
(green bars in Fig 3C). By 48h, the phosphorylation status of IBD biopsies cultured with 
otelixizumab had returned to about the same level as fresh normal mucosa. Notably, 
otelixizumab strongly inhibited phospho-proteins associated with T cell receptor 
signaling. Fig 3D shows a heatmap of the relative intensities of the phosphorylation 
status of receptor tyrosine kinases in biopsies from 6 CD and 6 UC cases, cultured with 
IgG or otelixizumab for 48h. Relative intensity values are shown in supplementary table 
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SIV, V and VI. While there was some variation between patients, overall the effects at 
48h were strong. For example in  Crohn’s disease patient 1, only 1 of the 39 kinases had 
a value of zero when cultured with IgG whereas in the biopsy cultured with 
otelixizumab, 26 of 39 kinases gave no signal. Likewise in ulcerative colitis patient 2, the 
biopsy treated with IgG gave a positive signal for all 39 kinases while the biopsy treated 
with otelixizumab gave no signal for 26 kinases. The average intensity values of 
phospho-proteins of IgG-treated vs. otelixizumab-treated samples were significantly 
different for the 48h values.  
Otelixizumab’s effects are dependent on interleukin-10 
Next, we focused on the role of IL-10 since in the array it was the only cytokine 
which increased with otelixizumab treatment. Supernatants of IBD LPMCs and explants 
cultured with otelixizumab showed increased IL-10 concentrations (Fig 4A). Biopsies of 
inflamed mucosa cultured with otelixizumab had higher relative IL-10 mRNA expression 
than the IgG treated biopsies as measured by RT-PCR (Fig 4A). When CD explants were 
cultured with otelixizumab and IL-10-neutralizing Ab, the IFN-γ concentration exceeded 
basal levels (Fig 4B). Unstimulated Crohn’s disease LPMCs cultured with otelixizumab 
showed reduced intracellular IFN-γ and increased intracellular IL-10 (Fig 4C). We next 
determined if the reduction in the phospho-protein profile in IBD mucosa cultured ex- 
vivo with otelixizumab was IL-10-dependent. Consistent with our earlier experiments, 
otelixizumab treatment reduced the phosphorylation levels in CD explants (Fig 4D 
showing one representative experiment); however, adding IL-10 neutralizing antibody 
along with otelixizumab inhibited this effect and the tissue maintained a high 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
16
phosphorylation status, far in excess of IgG control (Fig 4D, E showing the heatmaps of 
5 cases; supplementary  table VII). We confirmed the importance of IL-10 in our explant 
culture system by adding exogenous IL-10 to CD biopsies. IFN-γ and IL-17A levels were 
reduced in cultures treated with IL-10 (Fig 4F). 
 
Discussion 
Our results show that otelixizumab is profoundly anti-inflammatory when added 
to IBD LPMC and mucosal tissues from IBD patients. We must emphasize that this study 
was designed to show proof of principal that tolerising anti-CD3 antibodies have effects 
on T cells in inflamed tissue, and did not attempt to address why visilizumab, another 
tolerising anti-CD3 antibody, was not effective in ulcerative colitis in a randomized 
placebo controlled study
13
. We were well aware of the issues regarding the potential 
effects of dose of anti-CD3 antibodies and so we chose a dose of 1µg/ml for most of our 
studies since at this dose there was almost complete internalization of surface CD3 in 
blood T cells and in T cells in biopsies. The functional effects of otelixizumab were 
evidenced by the broad down-regulatory effects on pro-inflammatory cytokine and 
chemokine production, and even more remarkably, the reduction in phospho-protein 
levels in pathways unrelated to immune cells. For example, TrkA and TrkB are receptors 
for nerve growth factor and neurotrophins, ephrin receptors are involved in cell 
migration in many cell types, FGF receptors are involved in angiogenesis and wound 
healing, and HER2, HER3 and EGFR are involved in epithelial renewal. Since we can be 
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completely sure otelixizumab only targets T cells, these data show that T cell activation 
drives these myriad increased signaling pathways in IBD.  
We also show that otelixizumab increases IL-10 production by IBD biopsies and 
that the inhibitory effects of otelixizumab on phospho-protein reduction are IL-10 
dependent. This is very similar to previous studies where patients with type I diabetes 
treated with a tolerising anti-CD3 antibody showed increases in serum IL-10, and 
activation of blood T cells also increased IL-10 production 
27
. The new data that we 
present here show that the same effect occurs in activated T cells in tissues. It is very 
well established that IL-10 is a potent inhibitor of antigen presentation and the fact that 
we were able to show that otelixizumab reduced phosphorylated Lck and Zap70 in 
explants is consistent with both a decrease in antigen presentation and a loss of TcR 
signaling caused by the internalization of the TcR/CD3 complex. However, we must 
emphasize that we do not know if there is some signaling when otelixizumab binds to 
the CD3/TcR complex which delivers a signal to the T cell to shut down pro-
inflammatory cytokines and produce IL-10, similar to the effects of anti-CD46 and anti-
CD55 
28, 29
.  
An obvious question is whether otelixizumab is activating nascent IL-10 secreting 
regulatory T cells or whether it is driving Th1 or Th17 cells to produce IL-10. Our 
intracellular staining suggests the latter. However, we did examine if otelixizumab 
increased the number of CD4+, CD25+, FoxP3+ cells (Supplementary Figure 1), and 
indeed this was the case. Further studies are needed to define exactly the pathways by 
which otelixizumab is having such powerful effects and importantly, whether the effects 
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we have identified here are seen at lower doses of antibody. Although systemic and 
mucosal delivery of IL-10 for IBD therapy failed 
30, 31
, our study does re-inforce the 
important role of IL-10 in controlling inflammation in the human gut, and is consistent 
with reports on children with mutations in IL-10R who develop severe gut inflammation 
32, 33
. In addition, studies in humanized mice have shown that treatment with the 
tolerising anti-CD3 antibody teplizumab induces T cells which home to the gut and 
secrete IL-10 
34
. This study, however, was markedly different to ours because we 
investigated resident cells in human tissues.  
Our present work also builds on animal models of inflammatory disease where 
anti-CD3 antibodies have proved to be beneficial. For example, in mouse models of 
systemic lupus erythematosus, nasal and oral administration of anti-CD3 antibody 
results in decreased numbers of IL17+ follicular T helper cells and an increase in IL10-
producing CD4+CD25+ T cells 
35, 36
. Likewise, intravenous administration of anti-CD3 
antibodies in murine experimental autoimmune encephalomyelitis (EAE) is helpful by 
the induction of regulatory T cells 
37
; and intraperitoneal treatment with an Fc-
engineered anti-CD3 antibody showed beneficial effects with regard to symptoms, 
cytokine levels and T cell numbers in EAE
38
.  
We appreciate that a limitation of our study was the inability to track the fate 
and responsiveness of mucosal T cells treated with otelixizumab for prolonged periods 
of time because of the need to activate T cells in long-term culture to prevent cell death. 
Also, the often limited availability of biopsies and surgical specimens prevented us from 
working with a larger number of cases. Further, we used only one dose of antibody 
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throughout our study. Therefore the focus of future studies will be to evaluate the 
effect of different otelixizumab doses on mucosal T cells as the issue of the optimal anti-
CD3 in patients dose remains. For example, with regard to the failed clinical studies with 
visilizumab, it is not at all clear that 5 µg/kg for two days is a high enough dose to drive 
the internalization of the TcR/CD3 complex on all T cells in the tissues 
11, 12
. Our in vitro 
studies had on the other hand the advantage that we could interrogate closely how 
otelixizumab affects cytokines and phosphorylation patterns in the inflamed mucosa; 
something which would be difficult to do during a clinical trial. 
In conclusion, we show here by various experimental approaches that the anti-
CD3 antibody otelixizumab dampens inflammation in human tissue by a mechanism 
involving the induction of IL-10. Overall, we consider it premature to think tolerising 
anti-CD3 antibodies may not be a potential therapy for IBD on the basis of the 
previously failed clinical studies. Since otelixizumab can be given safely at much higher 
doses than other anti-CD3 antibodies, consideration should be given as to whether a 
clinical trial of this particular antibody in IBD may be justified.  
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Legends to figures   
 
Fig 1. Otelixizumab leads to CD3/ TCR internalization, but does not induce 
proliferation, inflammatory cytokine production, or cell death. A. Normal PBMCs were 
cultured with/ without otelixizumab for indicated times, stained with αCD4, αCD3, 
αTCRα/β or αhuman IgG Fc-PE and expression determined by flow cytometry. Culture 
with otelixizumab reduced expression of CD3 and TCRα/β on blood T cells. Graphs show 
the results of two experiments. B. UC biopsies were cultured with otelixizumab or IgG 
(1μg/ml) for 16h, tissue was manually disintegrated by rubbing it between frosted glass 
slides and repeated aspiration through a needle. Cells were stained and expression of 
CD3 analysed by flow cytometry. Data from one of two experiments with similar results. 
C. Normal LPMCs, CD LPMCs, and UC LPMCs were labeled with CFSE and cultured with 
indicated treatments for 96h. Histograms show CFSE dilutions indicating cell 
proliferation (gate set on CD2+ cells). Histograms show one of three experiments with 
similar results. D. IFN-γ and IL-17A concentrations in supernatants of LPMCs from 
healthy, inflamed CD and UC mucosa that were cultured with otelixizumab or YTH12.5. 
N=3 samples per group; Two-tailed paired t-test. Mean + SEM. E. Normal LPMCs and CD 
LPMCs were cultured in the presence of plate-bound αCD3 and soluble αCD28. 
Otelixizumab and IgG (1μg/ml) were added to the cultures immediately or after 16h of 
culture. IFN-γ concentration in the supernatants was measured after 48 hours of 
culture. Even when added at 16 hours, otelixizumab decreased IFN-γ production 
although statistical significance was only achieved for the former. n=3 per group, two-
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tailed paired Student t-test. Mean + SEM. In addition, normal LPMCs and CD LPMCs 
were cultured in the presence of otelixizumab, IgG and YTH (all 1μg/ml) as indicated. 
The second antibody was added after 3h and a wash-out of the first Ab. IFN-γ in the 
supernatant was measured by ELISA. HC n=4; CD n=3. One-way ANOVA with post-test. 
Mean + SEM. F. Percentages of apoptotic and dead LPMCs (from normal, CD and UC 
mucosa) after culture with indicated treatments for 48h. Normal LPMCs n=4, CD LPMCs 
n=5, and UC LPMCs  n=5.  
Fig 2. Otelixizumab modulates the inflammatory cytokine response in inflamed IBD 
tissue. A. IFN-γ and IL-17 concentrations in supernatants of mucosal explants of 
inflamed CD colon and UC colon. Explants were cultured with IgG or otelixizumab (both 
1μg/ml) for 16h. CD, n=20; UC, n=14. Two-tailed paired t-test. Mean + SEM. B. Mucosal 
explants from active CD colon were cultured with IgG or otelixizumab for 16 h and then 
lysed. T-bet, RORγt and ß-actin (loading control) were determined by western blot. 
Shown is one representative blot of 5 experiments with similar result. The graph shows 
the relative optical density of the bands (n=5 blots). Values are the ratios between IgG 
or otelixizumab-treated samples and the untreated control.  Mean +SD. The * indicates 
p<0.0001. Two-tailed paired Student’s t-test. C, D. Inflamed CD mucosal explants (C) and 
UC colon (D) explants were cultured with IgG or otelixizumab for 16h. Supernatants 
were probed onto a multiplex cytokine array. Relative pixel intensities of cytokine levels 
of one representative array of a single Crohn’s patient and a single UC patient are 
shown. E. Heatmaps showing the relative signal intensities for the analysed cytokines. 
Plotted are the results from 6 inflamed CD samples and 6 UC inflamed samples which 
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had been cultured with IgG or otelixizumab for 16h; the data of the 6 cases each were 
averaged for each cytokine and all average values were analysed by comparing them 
with the Wilcoxon rank-sum test (i.e. all cytokine averages of CD IgG vs all cytokine 
averages of CD otelix). CD n=6, UC n=6. CD IgG vs. CD otelix p=0.0004; UC IgG vs UC 
otelix p=3.4x 10-
5
.  
 
Fig 3. Otelixizumab alters the kinase phosphorylation status in inflamed Crohn’s 
disease and ulcerative colitis tissue.  A. Representative phosphorylation levels of 
various receptor-tyrosine kinases and signaling molecules in lysates of healthy colonic 
mucosa, inflamed CD mucosa, and inflamed UC mucosa as analysed by a multiplex 
phosphorylation array. Biopsies were immediately snap frozen after being taken from 
the patient. B. Heatmap showing the relative signal intensities of the phospho-proteins 
in 4 normal colon samples, 7 CD and 6 UC samples. The relative values between 1700-
4000 were given the same red colour to simplify the heatmap. The phospho-intensities 
of all values of the 4 controls, 7 CD, and 6 UC, respectively, were averaged for the 
particular group and analysed by comparing them with the Wilcoxon rank-sum test. 
Control vs. CD p=1.08x10-
13; Control vs. UC p=2.910-14. C. Representative 
phosphorylation levels of kinases in lysates of one inflamed CD explants and one 
inflamed UC explants cultured for 48h with either IgG or otelixizumab (both 1μg/ml). D. 
Heatmap showing the relative signal intensities for the analysed phosphorylated 
kinases. Plotted are the results of inflamed samples from six Crohn’s patients (CD1, CD2, 
etc.) and six UC patients (UC1, UC2, etc.) at 48h culture with otelixizumab. The relative 
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values between 1700-4000 were given the same red colour to simplify the heatmap. All 
samples show a reduction in phosphoproteins at 48h; Wilcoxon rank-sum test, n=6. CD 
IgG vs otelix p=1.08x10-
7; UC IgG vs. otelix p=1.4 x10-6.  
 
Fig 4. Otelixizumab promotes an anti-inflammatory response via IL-10. A. LPMCs from 
normal, CD and UC mucosa were cultured with IgG or otelixizumab (both 1μg/ml) for 
48h as indicated. CD and UC explants were cultured for 16h with IgG or otelixizumab. IL-
10 concentrations in supernatants were measured. LPMCs n=4; explants n=18 (CD) and 
n=14 (UC). Two-tailed t-test. Mean + SEM. To measure the relative expression of IL-10 
mRNA by qRT-PCR, mucosal biopsies of inflamed CD and UC colon were cultured with 
IgG, otelixizumab (both 1μg/ml) for 24h. UC cases in blue n=6; CD cases in black n=5. 
p=0.04, Wilcoxon rank sum test. B. Mucosal biopsies of inflamed CD colon were cultured 
with IgG, otelixizumab (1μg/ml), neutralizing anti-IL-10 (10μg/ml) or the matching 
isotype Ab for 16h. IL-10 in supernatants was measured by ELISA. Otelixizumab 
abolished the spontaneous IFN-γ production, but this effect was reversed by anti-IL-10. 
Shown are the means + SEM of three independent experiments. One way ANOVA with 
post-test. C. Unstimulated CD LPMCs were cultured as indicated for 16h, then for 
further 4h with monensin before intracellular staining of IFN-γ and IL-10 was performed. 
Plots show cytokine expression in CD2+ LPMCs and demonstrate one of two 
experiments. D. Explants of cultures like shown in (A) were subjected to the RTK-
phospho-array. Shown is the result of one of five independent experiments. E. The 
heatmap summarizes the data of the five separate samples. Wilcoxon rank-sum test, 
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otelix + anti-IL10 vs. otelix + isotype, p= 6.6x 10
-8
. F. CD explants were cultured for 16h 
as indicated. Recombinant IL-10 was used at 10ng/ml, antibodies at 1μg/ml. IFN-γ and 
IL-17A were determined by ELISA in supernatants. Exogenously added IL-10 clearly 
diminishes IFN-γ and IL-17A production. N=3. One way ANOVA with post-test. Mean 
+SEM. 
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Legends to Supplementary Materials 
 
Supplementary Figure 1. 
A. Normal LPMCs and B. CD LPMCs were cultured in the presence of otelixizumab, IgG and YTH 
(1μg/ml) as indicated. The second antibody was added after 3h and a wash-out of the first Ab. 
IL-17A and IL-2 levels in the supernatants were measured by ELISA. HC n=4; CD n=3. One-way 
ANOVA with post-test. Mean + SD.  
Supplementary Figure 2. A. LPMCs from CD mucosa were cultured with IgG or otelixizumab for 
24h. Foxp3 was stained intracellularly. Histograms show Foxp3 signal in the CD4+ CD25+ 
population. Histograms show one of six experiments. B, C. Graphs show percentage (B) of 
CD4+CD25+Foxp3+ cells and mean fluorescence intensity (C) in three CD as well as three 
healthy LPMCs cultured with either IgG or otelixizumab (both 1μg/ml) for 24h. Mann-Whitney-
test. Depicted is the median. 
Supplementary Table I 
Patient and disease characteristics of the CD and UC patients recruited for this study.  
Supplementary Table II 
Relative cytokine values that were measured in the explant supernatants by protein array. 
Shown are the relative pixel intensities of the dots on the array (mean of duplicates per 
analyte). Explants of six Crohn’s disease patients had been cultured for 16h with IgG or 
otelixizumab. Shown is also the table used for statistical testing. 
Supplementary Table III 
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Relative cytokine values that were measured in the explant supernatants by protein array. 
Shown are the relative pixel intensities of the dots on the array (mean of dublicates per 
analyte). Explants of six ulcerative colitis patients had been cultured for 16h with IgG or 
otelixizumab. Shown is also the table used for statistical testing. 
Supplementary Table IV 
Relative phosphorylation levels that were measured in the explant lysates by phospho-protein 
array. Analysed were four healthy colon specimens, seven inflamed CD and six inflamed UC 
specimens. Specimens were immediately snap-frozen and untreated. Shown is also the table 
used for statistical testing. 
Supplementary Table V 
Relative phosphorylation levels that were measured in the explant lysates by phospho-protein 
array. Explants of six Crohn’s disease patients had been cultured for 48h with IgG or 
otelixizumab. Lysates were subjected to the phospho-protein array and relative intensities of 
the dots (in duplicates) were measured. Shown is also the table used for statistical testing. 
Supplementary Table VI 
Relative phosphorylation levels that were measured in the explant lysates by phospho-protein 
array. Explants of six ulcerative colitis patients had been cultured for 48h with IgG or 
otelixizumab. Lysates were subjected to the phospho-protein array and relative intensities of 
the dots (in duplicates) were measured. Shown is also the table used for statistical testing. 
Supplementary Table VII 
Relative phosphorylation levels that were measured in the explant lysates by phospho-protein 
array. Explants of five Crohn’s disease patients had been cultured for 24h as indicated. Lysates 
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were subjected to the phospho-protein array and relative intensities of the dots (in duplicates) 
were measured. Shown is also the table used for statistical testing. 
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Supplementary Table I 
 
Patient characteristics 
Crohn’s disease  n=85          Nr  Median (range) 
Age              85  31.1 (15‐57) 
Female              45 
Male              40 
Disease location 
‐ Ileum & colon          38 
‐ colon only          47 
Treatment 
‐ 5‐AZAs            21 
‐ 5‐AZAs  & steroids        35 
‐ 5‐AZAs & azathioprine/methotrexate/other  29 
 
 
Ulcerative colitis  n=61          Nr  Median (range) 
Age              61  34.5  (13‐65) 
Female              29 
Male              32 
Disease location 
‐ distal colon          39 
‐ pan‐colitis          22 
Treatment 
‐ 5‐AZAs            16 
‐ 5‐AZAs  & steroids        30   
‐ 5‐AZAs & azathioprine/methotrexate/other  15 
 
 
Note: patients on anti‐TNF drugs were not recruited for this study 
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Supplementary Table II
cytokines Crohn's disease explant supernatants
CD1 CD2 CD3 CD4 CD5 CD6 AVERAGE
16h + IgG 16h + Otelix 16h + IgG 16h + Otelix 16h + IgG 16h + Otelix 16h + IgG 16h + Otelix 16h + IgG 16h + Otelix 16h + IgG 16h + Otelix 16h + IgG 16h + Otelix
C5a 23656.5 23574.5 5079.5 2877 8577.5 2111.5 10224 5679 8179.5 1689.5 3809.5 575.5 9921.08333 6084.5
CD40 ligand 4518 3388 2483.5 3354.5 8167.5 0 5546 1023 4436.5 0 1862.5 670.5 4502.33333 1406
G-CSF 25618 10045.5 4608 1024.5 12575.5 7290.5 8221.5 2346 6577 5832 3456 204.5 10176 4457.16667
GM-CSF 5713 1183.5 1638 1000 7002.5 806.5 6798.5 631 5438 645 1228.5 200 4636.41667 744.333333
GROalpha 25507 10396.5 5466.5 486.5 14656.5 17691.5 18996.5 9446 151970 14153 4099.5 97 36782.6667 8711.75
I-309/CCL1 2213 1600.5 1844.5 574 1616.5 0 9765 27 7812 0 1383.5 114 4105.75 385.916667
sICAM-1 23166.5 26668.5 15217.5 14182 17553 2080.5 14665 2289.5 11732 1664 11413 2836 15624.5 8286.75
IFNg 8544.5 6704 6250 4110 6331 1033.5 7746 550 6196.5 826.5 4687.5 822 6625.91667 2341
IL1 alpha 67.5 976.5 1934 586 11186.5 0 5679 225 4543 0 1450.5 117 4143.41667 317.416667
IL1 beta 19663 4999.5 6878.5 4162.5 11185.5 7065.5 16447 2346 131570 0 5158 832.5 31817 3234.33333
IL1ra 25463 28341 16973 18143.5 21239 17516 15446.5 10166 123570 14012 12729.5 3628.5 35903.5 15301.1667
IL2 2900 1421 1311.5 3292.5 2367.5 0 4022 1344 32170 5652 983 658.5 7292.33333 2061.33333
IL4 1382.5 655 680 621 2279 0 1079 0 863.5 0 510 124.5 1132.33333 233.416667
IL5 2277.5 1002 968.5 448 1532.5 0 1163 267 930 0 726 89.5 1266.25 301.083333
IL6 25298 6631.5 15938 1424 20742.5 15264 22679 6021.5 18143 12211 11953.5 284 19125.6667 6972.66667
IL8 25394.5 28285 17219.5 12031.5 21378 18580 26449 4990 21159 14864 12914.5 2406 20752.4167 13526.0833
IL10 0 3964 396.5 2129.5 2774.5 3681.5 336 1977.5 268 2945 297.5 825 678.75 2587.08333
IL12 p70 0 1070 300 292 3948.5 0 4679 223 3743 0 225 58 2149.25 273.833333
IL13 3261.5 3478.5 1393 2857 5972 0 279 0 223 0 1044.5 571 2028.83333 1151.08333
IL16 7644 4285.5 6917 2862 6287.5 168.5 5467.5 344 4374 134 5187.5 572 5979.58333 1394.33333
IL17 10795 3246 6884 3950 7237.5 0 8877 578.5 7101 0 5163 790 7676.25 1427.41667
IL25 3870.5 1639 1668.5 1151 3043.5 0 2264 0 1811 0 1251.5 230 2318.16667 503.333333
IL23 12422 5479 4600.5 3021.5 8224.5 600 4479 548 3583 0 3450.5 604 6126.58333 1708.75
IL27 18485.5 9713 4167.5 1140.5 14732 7209 16344 805 13075 5767.2 3125.5 228 11654.9167 4143.78333
IL32alpha 0 848 521.5 0 4152.5 0 468 0 374 480 391 0 984.5 221.333333
IP-10/CXCL10 0 684 107 0 2629.5 0 5590 664 4472 0 80 0 2146.41667 224.666667
I-TAC/CXCL11 1492.5 1394.5 153.5 634.5 2113 0 1645 1554 1316 0 115 126.5 1139.16667 618.25
MCP-1/CCL2 2240.5 892 583 659 1195 0 997 0 797 0 437 131.5 1041.58333 280.416667
MIF 25220 28171.5 17226.5 18094 21262.5 18416 23445.5 19778 18756 14732.5 12919 3618 19804.9167 17135
MIP-1alpha/CCL3 5144.5 1843.5 3502.5 2951.5 2499.5 0 2246 244 1796 0 2626 590 2969.08333 938.166667
MIP-1beta/CCL4 3783 2005 852 332 2488.5 0 1922 134 1537 0 639 66 1870.25 422.833333
Serpin E1 25454.5 27976.5 17198.5 10010 21277 18333.5 879 746 703 14666 12898.5 2002 13068.4167 12289
RANTES/CCL5 736 2462 3624.5 2017 6609 0 8799 640.5 7039.5 0 2718.5 403 4921.08333 920.416667
CXCL12 0 498 39 0 3033.5 0 6643 446 5314.5 0 29.5 0 2509.91667 157.333333
TNFa 111 398 0 0 1594.5 0 645 213 516 0 0 0 477.75 101.833333
sTREM1 1146.5 479.5 255.5 560.5 937 0 1044 879 835 0 191.5 112.5 734.916667 338.583333
U-test 0.0004
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Supplementary Table III
cytokines Ulcerative colitis explant supernatants
UC1 UC2 UC3 UC4 UC5 UC6 AVERAGE
16h + IgG 16h + Otelix 16h + IgG 16h + Otelix 16h + IgG 16h + Otelix 16h + IgG 16h + Otelix 16h + IgG 16h + Otelix 16h + IgG 16h + Otelix 16h + IgG 16h + Otelix
C5a 5140.5 2283 5060.5 1100.5 11644.5 7747 5654.5 2385.5 4554.0 880.0 8849 484 6817.2 2480.0
CD40 ligand 9186.5 5959.5 6730.5 3807 4295.5 1863 10105 6227.5 6057.0 3045.0 3264.5 1675 6606.5 3762.8
G-CSF 3946.5 2655 11759 6272 19103.5 11453 4341.5 2774.5 10583.0 5017.0 14518 2759 10708.6 5155.1
GM-CSF 2701 1760 4909.5 0 12435 0 2971 1839 4418.0 0.0 9450 0 6147.4 599.8
GROalpha 16799.5 16179.5 11498.5 7859 13439 8866.5 18479.5 16907 10348.5 6287.0 10213 3457.5 13463.0 9926.1
I-309/CCL1 2757.5 2522.5 4927.5 0 9478.5 0 3033.5 2636 4434.5 0.0 7203 0 5305.8 859.8
sICAM-1 17107.5 16181 9139 1765.5 16714 10819 18818 16909 8225.0 1412.0 12702.5 776 13784.3 7977.1
IFNg 7015.5 2986.5 8998 2593 11553 7481 7717 3120 8098.0 2074.0 8780 1140 8693.6 3232.4
IL1 alpha 7030.5 5719.5 5129 1365 6360.5 178 7733 5976 4616.0 0.0 4833 55.5 5950.3 2215.7
IL1 beta 2814 1947.5 3371.5 0 2540.5 356 3095 2035 3034.5 0.0 1930 0 2797.6 723.1
IL1ra 17163 15458 8460.5 5863 16278 11361 18879 16153 7614.5 4690.0 12371 2579 13461.0 9350.7
IL2 3726 0 2225.5 0 3863.5 1032.5 4098 0 2002.5 0.0 2936 0 3141.9 172.1
IL4 1709.5 529.5 3833.5 0 4918 2551 1880.5 553 3450.5 0.0 3737.5 0 3254.9 605.6
IL5 1676.5 350.5 4852 0 5985 0 1844 366.5 4366.0 0.0 4548 0 3878.6 119.5
IL6 4592.5 7362.5 11814.5 6833 20816.5 14639.5 5051.5 7693.5 10633.0 5466.0 15820.5 3006.5 11454.8 7500.2
IL8 17035 16205.5 11577.5 7448.5 24541 17286.5 18738.5 16934.5 10419.5 5958.0 18651 3277 16827.1 11185.0
IL10 3676 5092 1566.5 4173 3613 0 4043 6321 1409.5 4338.0 1836 3745 2842.2 3293.3
IL12 p70 1644.5 386 2499 0 4212 0 1808.5 403 2249.1 0.0 3201 0 2602.4 131.5
IL13 5924.5 1856 2645.5 274.5 3012.5 2073.5 6516.5 1939 2380.5 219.0 2289 120 3794.8 1080.3
IL16 15861.5 12426.5 5060.5 7491 14839.5 13397.5 17447.5 12985.5 4554.5 0.0 11278.02 3296 11506.9 8266.1
IL17 5117 1035.5 6656.5 2213.5 7282 1037.5 5628 1082 5990.0 1770.0 5534 973 6034.6 1351.9
IL25 3745 1685 6520 669.5 8072.5 0 4119 1760.5 5868.0 535.0 6135.5 294.5 5743.3 824.1
IL23 12505 9936 9175.5 4480.5 12674 5736.5 13755.5 10383 8257.0 3584.0 9632 1971 10999.8 6015.2
IL27 4496 4066.5 10304 2510.5 20048.5 12106.5 4945 4249.4925 9273.0 2008.0 15236 1104 10717.1 4340.8
IL32alpha 3266.5 1081.5 5335.5 1285 11438 0 3593.5 1130.5 4801.5 0.0 8692 0 6187.8 582.8
IP-10/CXCL10 1507 699.5 2361.5 0 4284.5 0 1657 730 2125.5 0.0 3256 0 2531.9 238.3
I-TAC/CXCL11 3310 1318 2514.5 0 3043 6249 3641 1377 2263.0 0.0 2312.5 0 2847.3 1490.7
MCP-1/CCL2 3773.5 1293 2407.5 14.5 6218 4869 4150.5 1351.5 2166.0 11.0 4725 6 3906.8 1257.5
MIF 17143.5 16149 11298 7667 26003 21605 18857 16875.5 10168.0 6133.0 19762.5 3373.5 17205.3 11967.2
MIP-1alpha/CCL3 6330 3241.5 5947 1585 16469.5 4527 6963 3387 5352.0 1268.0 12516 697.5 8929.6 2451.0
MIP-1beta/CCL4 2995 960.5 6221 1022.5 18286.5 5039 3294.5 1003.5 5598.0 0.0 13897 449 8382.0 1412.4
Serpin E1 16434 16263.5 11656.5 7125.5 31253.5 17033 18077 16995 10490.5 5700.0 23752 3135 18610.6 11042.0
RANTES/CCL5 8521.5 14547.5 9559 4502.5 12788.5 3041.5 9373.5 15202 8603.0 3602.0 9719 0 9760.8 6815.9
CXCL12 767.5 695 3422 0 4972 0 844.5 726 3079.0 0.0 3778 1981 2810.5 567.0
TNFa 1237.5 0 1489 0 3784 97.5 1361.5 0 1340.0 0.0 2875 0 2014.5 16.3
sTREM1 2344 839.5 2050.5 0 6983 6093.5 2578 877 1845.0 0.0 5307 0 3517.9 1301.7
U-test 0.000034
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Supplementary Table IV
Phosphorylation in untreated explants
Healthy1 Healthy2 Healthy 3 Healthy 4 CD1 CD2 CD3 CD4 CD5 CD6 CD7 UC1 UC2 UC3 UC4 UC5 UC6
EGFR/ErbB1 0 105 0 0 1195 202 636 1168 1102.5 247 1032.5 691.5 3177 2736.5 2478 2451.5 2536.5
HER2/ErbB2 0 0 0 0 1457.5 339 710 1219 1344.5 414 1077 837.5 2877 1696.5 2244 2351.5 2295.5
HER3/ErbB3 0 220.5 0 35 1551 343.5 495.5 1102 1430 465 974 1017 2798 752 2182.5 2150 2356
FGFR1 0 0 37.5 69 872.5 243.5 352.5 780.5 804 298.5 689 691.5 2951.5 3649.5 2302.5 2359 2392.5
FGFR3 0 0 85.5 57.5 720 193 382.5 568 664 236.5 502 512 2443.5 1996.5 1905 2018 1656
FGFR4 0 0 0 0 710.5 247.5 358.5 588 655 302.5 519 376 3074 1432.5 2397 2018 1670
InsR 0 5.5 0 0 1172 192.5 381.5 700 1080 246 618 637 2897 462.5 2259 1660.5 1615.5
IGF-IR 0 58 66 23.5 918 147 188 749.5 846.5 179.5 662 464 2347 285.5 1830.5 1962.5 1718
TrkA/NTRK1 0 0 0 0 1321.5 101 554 596 1218.5 123.5 526 756 1544 1943.5 1204 889.5 778
TrkB/NTRK2 0 0 0 0 928 140 321.5 579 855 171.5 511 355 1127.5 1346 879 838 1018
Met/HGFR 0 0 0 0 176.5 14 0 267 162 167.5 236 163 1770.5 634.5 1380 737 803
Ron/MST1R 0 0 0 0 236.5 0 0 255 218 0 225 113 910 673 709 780 959.5
Ret 0 0 0 0 241 105 0 293.5 222 128.52 259 115 1573 847.5 1226 1117 1814.5
ALK 0 0 0 0 469.5 0 0 435 433 0 384.5 175 1264 3349 985 987.5 2858
PDGFR 0 0 0 0 807 0 30.5 499 744.5 0 441 351 875 2242 682.5 564.5 1901
c-kit/SCFR 0 0 0 0 1468 25.5 258 620.5 1353.5 31.5 548.5 519 430 1035.5 335.4 345 1729
FLT3/Flk2 0 0 0 0 844.5 0 27 386.5 778 0 341 375.5 472.5 617.5 368.5 311.5 1527
M-CSFR/CSF-1R 0 0 0 0 691 0 0 355 637 0 313 263.5 411.5 289 320 260.5 1137
EphA1 0 0 0 0 713.5 0 0 673.5 658.5 24.5 595 518 180 2291 140 134.5 1158
EphA2 0 0 0 0 461 20 0 477 425 0 421 404 75 1747.5 0 64 1394
EphA3 0 0 0 0 338.5 0 0 296.5 312 76.5 262 302.5 187 1374 145 138 994.5
EphB1 0 0 0 0 352.5 0 0 304 325 0 268.5 290 190 866 148 156 727.5
EphB3 0 0 0 0 527.5 80 0 386.5 486.5 97.5 341 566 299 604.5 233 189 678.5
EphB4 0 0 0 0 156.5 3 0 363.5 144 3.5 321.5 233 25 1920.5 0 67 108.35
Tyro3/Dtk 0 0 0 0 0 0.5 0 316.5 0 0 279.5 122 144 1346.5 112 33 0
Axl 0 0 0 0 159 28 0 184 146 34.5 162 152 101 1227 78 90 396
Tie2/TEK 0 0 0 0 773 208.5 227 385 712 255.5 340 561.5 428 1270.5 333.5 290 857
VEGFR2/KDR 0 0 0 0 598.5 118 282 319.5 551.5 134 282.5 552 119.5 726.5 93 73 444
Akt/PKB/Rac Thr308 0 0 0 0 1513 475.5 843.5 1097 1395 582 969.5 1147.5 1396 3874 1088 824 2743
Akt/PKB/Rac Ser473 0 0 0 0 1443.5 460.5 725.5 1117 1331 563 987 1262.5 1374 3815.5 1071 821 2960
p44/42 MAPK (ERK1/2) 32.5 0 33.5 64.5 1923 682 617.5 856 1773.5 834 756 980.5 466 3597 363 332 1955
S6 ribos. Protein 0 0 0 0 1349 358.5 618.5 677.5 1244 438 598 867.5 991.5 3998 773 717 2160.5
c-Abl 0 0 0 0 686 214.5 314 492.5 632 279 435 434.5 639 1409 498 304 963.5
IRS-1 0 120.5 0 0 1197 304 641.5 1226.5 1103 372 1084 793 646.5 2803 504.5 453.5 696.5
Zap-70 220 333.5 115.5 87.5 1673.5 629 972.5 1280 1543 769 1131.5 1311.5 987 3304.5 769 676.5 1801.5
Src 131.5 147 203 0 1591.5 590.5 845 1211 1467.5 722 1070.5 1186 876 3113 683 667.5 2020
Lck 75 34 110 112 1207.5 454 677.5 879 1113 555.5 777 815.5 1023 2854 797.5 912.5 2223
Stat1 37.5 213.5 67 179 1610 547 862.5 946.5 1484 669 836.5 1068.5 1899 3533 1481.5 1382.5 2555
Stat3 173 301 69 98.5 1598.5 686.5 1023.5 1202.5 1474 840.5 1063 1390.5 2448 3976 1909 1817.5 2811.5
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average CD average HC average UC average HC
797.5714286 26.25 2345.166667 26.25
937.2857143 0 2050.333333 0
908.7142857 63.875 1875.916667 63.875
577.2142857 26.625 2391.083333 26.625
466.5714286 35.75 1755.166667 35.75
483 0 1827.916667 0
627.1428571 1.375 1588.583333 1.375
527.2142857 36.875 1434.583333 36.875
634.3571429 0 1185.833333 0
500.8571429 0 927.25 0
146.1428571 0 914.6666667 0
133.5 0 690.75 0
178.4314286 0 1115.5 0
246 0 1603.083333 0
360.2857143 0 1102.666667 0
615.0714286 0 732.3166667 0
339.5714286 0 612.0833333 0
285.1428571 0 446.9166667 0
380.7142857 0 736.9166667 0
257.7142857 0 614.0833333 0
183.6428571 0 523.5 0
178.5714286 0 396.25 0
274.1428571 0 428.3333333 0
141.7142857 0 392.3083333 0
85.21428571 0 292.9166667 0
101.9285714 0 340.6666667 0
414.4285714 0 623.4166667 0
326.5714286 0 334.6666667 0
982.2142857 0 1845.416667 0
946.7857143 0 1884 0
1063.142857 32.625 1282.25 32.625
754.7857143 0 1584.583333 0
436.1428571 0 708 0
846.8571429 30.125 982.8333333 30.125
1142.642857 189.125 1475 189.125
1071.142857 120.375 1424.25 120.375
809.0714286 82.75 1437.583333 82.75
993.6428571 124.25 1986.583333 124.25
1126.928571 160.375 2392.083333 160.375
U test
1.085326e-
13* U test 2.9e-014*
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Supplementary Table V
Phosphorylation levels in treated Crohn's disease explants
AVERAGE
CD1 CD1 CD2 CD2 CD3 CD3 CD4 CD4 CD5 CD5 CD6 CD6 Crohn's
IgG48h Ote 48h IgG48h Ote 48h IgG48h Ote 48h IgG48h Ote 48h IgG48h Ote 48h IgG48h Ote 48h IgG48h Ote 48h
EGFR/ErbB1 2948 985 574.5 0 201 56 2734 1123 873 153 1172 153 1417.08333 411.666667
HER2/ErbB2 2809.5 730 512.5 0 190 0 997 210 553 234 505 243 927.833333 236.166667
HER3/ErbB3 2523 647 388 0 174.5 0 823 55 705 275.5 577 79.5 865.083333 176.166667
FGFR1 2849 916 997.5 0 898.5 915.5 2661 522 1101 0 661 0 1528 392.25
FGFR3 2255 580 259 0 0 0 1105 0 314 0 1025 531 826.333333 185.166667
FGFR4 2305 503.5 128.5 0 0 0 1002 0 115 0 1221 0 795.25 83.9166667
InsR 1817 90 47 0 0 0 396 110 75 0 1175.5 27 585.083333 37.8333333
IGF-IR 2144.5 300.5 155.5 0 0 0 301 0 177.5 0 620 305 566.416667 100.916667
TrkA/NTRK1 856.5 0 242.5 0 0 101.5 1132 215.5 663 237 535 104 571.5 109.666667
TrkB/NTRK2 954 41 27 0 0 0 775.5 101 113 0 67.5 37 322.833333 29.8333333
Met/HGFR 782 0 0 0 0 0 51 0 75.5 0 115.5 0 170.666667 0
Ron/MST1R 979 0 0 0 0 0 0 0 53 0 70.5 225 183.75 37.5
Ret 1616 0 223.5 0 0 0 223 0 117 27 663 0 473.75 4.5
ALK 843 267.5 398.5 0 297 647.5 3011 0 205 67.5 273 0 837.916667 163.75
PDGFR 253 0 219.5 0 0 432.5 231 0 245 51.5 117 0 177.583333 80.6666667
c-kit/SCFR 301 0 0 0 0 0 0 0 237 0 51 0 98.1666667 0
FLT3/Flk2 478 0 0 0 0 0 373.5 22 0 0 31.5 0 147.166667 3.66666667
M-CSFR/CSF-1R 801.5 0 0 0 0 0 225 0 0 0 0 0 171.083333 0
EphA1 0 0 249 0 0 266 93 32 145 0 67.5 0 92.4166667 49.6666667
EphA2 31.5 0 101 0 0 0 113 11 79.5 0 88.5 0 68.9166667 1.83333333
EphA3 215 0 0 0 0 0 0 0 533 0 103.5 23.5 141.916667 3.91666667
EphB1 294.5 0 35.5 0 0 0 227.5 0 24 0 0 0 96.9166667 0
EphB3 602.5 0 43 0 0 0 115.5 77.5 179 72 225 113 194.166667 43.75
EphB4 107.5 0 369 0 0 87 318.5 0 105.5 0 73 0 162.25 14.5
Tyro3/Dtk 158 0 324 0 0 0 443 72 279 51 124 0 221.333333 20.5
Axl 375.5 0 264.5 0 0 0 501 213 66.5 0 137.5 0 224.166667 35.5
Tie2/TEK 826.5 0 318.5 0 0 69.5 0 135 129 0 220 0 249 34.0833333
VEGFR2/KDR 594 0 67 0 0 0 0 0 345 125 257.5 0 210.583333 20.8333333
Akt/PKB/Rac Thr308 2276 392 1874 250 1489 693 1992 459.5 943 337 69 0 1440.5 355.25
Akt/PKB/Rac Ser473 1696.5 401 1688.5 137 1034.5 836.5 1883.5 123 201 0 88.5 27 1098.75 254.083333
p44/42 MAPK (ERK1/2) 695 0 843.5 0 412 59 223 0 115 0 175 45.5 410.583333 17.4166667
S6 ribos. Protein 1384 0 1189.5 42 354 332 307 0 93 0 223 73 591.75 74.5
c-Abl 766 0 579.5 0 0 0 453.5 0 958 432.5 555 110 552 90.4166667
IRS-1 793 0 2383.5 928 1313.5 938 1195 504 1025 72 35.5 103 1124.25 424.166667
Zap-70 1317.5 0 2518.5 1251 1422.5 865.5 2013 588 2537 304 103 0 1651.91667 501.416667
Src 1131.5 0 1903 662 901 529.5 1122.5 337 1010 335 993 0 1176.83333 310.583333
Lck 1259 0 1886.5 433 614 483.5 657 228.5 793 110 1150 23 1059.91667 213
Stat1 1636 0 1595.5 709.5 700 443 895 115 1887.5 62 773 72 1247.83333 233.583333
Stat3 2144 295.5 3374.5 2220 2283 1413.5 2245.5 259 2310 275 1095 554 2242 836.166667
U-test 1.08e-07*
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Supplementary Table VI
Phosphorylation levels in treated Ulcerative colitis explants
AVERAGE
UC1 UC1 UC2 UC2 UC3 UC3 UC4 UC4 UC5 UC5 UC6 UC6 UC
IgG48h Ote 48h IgG48h Ote 48h IgG48h Ote 48h IgG48h Ote 48h IgG48h Ote 48h IgG48h Ote 48h IgG48h Ote 48h
EGFR/ErbB1 2591 2024.5 881.5 457 903 980.5 773 331 905 278 2103 587 1359.41667 776.333333
HER2/ErbB2 2403.5 1564 695.5 134 755 656.5 885 238.5 793 589 953.5 423 1080.91667 600.833333
HER3/ErbB3 2567 1584.5 855 252.5 793 1148.5 893 593.5 845 347 1037 182 1165 684.666667
FGFR1 2449 1916.5 1052 560 1215.5 1686.5 1034 378 925 214 883 55 1259.75 801.666667
FGFR3 1851.5 1389.5 772.5 109 728 717.5 753 0 1235.5 663 766 32 1017.75 485.166667
FGFR4 1891 1293.5 714 79.5 639.5 507.5 554 0 598.5 0 778 0 862.5 313.416667
InsR 1892 987 704 0 342 433.5 225 0 538 0 701 0 733.666667 236.75
IGF-IR 1943 1080.5 648 106.5 447 308.5 543 138 201.5 0 331 325.5 685.583333 326.5
TrkA/NTRK1 493.5 0 613.5 0 688 810 689 110.5 553 0 449 143 581 177.25
TrkB/NTRK2 568 0 566.5 0 491 432 223 73 493.5 113 661 37.5 500.5 109.25
Met/HGFR 407 0 495.5 0 196.5 0 239.5 65.5 117 72 338.5 145 299 47.0833333
Ron/MST1R 445 0 469 0 339 0 210 103 193 51.5 278 0 322.333333 25.75
Ret 961.5 0 669.5 0 860 0 793 347 225 22.5 993 289 750.333333 109.75
ALK 1124 0 957.5 323.5 1131 1103.5 885.5 0 554 173.5 1120 79 962 279.916667
PDGFR 182.5 0 586 0 456 487.5 331 0 203 0 557.5 123 386 101.75
c-kit/SCFR 0 0 633 0 0 0 0 0 0 0 301 0 155.666667 0
FLT3/Flk2 0 0 408 0 27 0 55 0 101 0 75 0 111 0
M-CSFR/CSF-1R 0 0 518 0 139 0 98.5 173 201 0 0 0 159.416667 28.8333333
EphA1 0 0 506 0 404.5 447 320 0 102.5 0 71.5 0 234.083333 74.5
EphA2 0 0 517.5 0 80 138 43 0 0 0 0 0 106.75 23
EphA3 0 0 444.5 0 35 0 27 0 45 0 75 11 104.416667 1.83333333
EphB1 0 0 314.5 0 0 0 115 27.5 203 73 0 0 105.416667 16.75
EphB3 0 0 252.5 0 0 0 105 0 0 0 0 0 59.5833333 0
EphB4 0 0 246.5 0 12 5 98 0 235 43.5 0 23 98.5833333 11.9166667
Tyro3/Dtk 0 0 185.5 0 0 0 128 0 98 0 0 0 68.5833333 0
Axl 0 0 224.5 0 0 0 745 114 0 0 0 0 161.583333 19
Tie2/TEK 0 0 337 0 0 0 332 88 1001 338.5 0 0 278.333333 71.0833333
VEGFR2/KDR 0 0 206 0 0 0 405 0 205 75 88 0 150.666667 12.5
Akt/PKB/Rac Thr308 0 0 666.5 0 739 674.5 287.5 0 67 0 237 0 332.833333 112.416667
Akt/PKB/Rac Ser473 0 0 983 211.5 1057 528.5 118.5 31 103.5 0 244 0 417.666667 128.5
p44/42 MAPK (ERK1/2) 0 0 964 0 0 0 345.5 70.5 245 0 178 0 288.75 11.75
S6 ribos. Protein 0 0 568 0 574.5 0 101 0 773 220 240 53 376.083333 45.5
c-Abl 0 0 243 0 0 0 668.5 0 109.5 0 1041 178 343.666667 29.6666667
IRS-1 9.5 0 626 64 50 212.5 31 0 211 0 370.5 57 216.333333 55.5833333
Zap-70 362.5 0 671 112.5 133.5 320.5 0 0 443 345 538 37.5 358 135.916667
Src 0 0 694 1 0 0 0 28.5 887 287 110 0 281.833333 52.75
Lck 0 0 565.5 0 0 0 102.5 375 1057 37 553 175 379.666667 97.8333333
Stat1 0 0 569 0 93 100.5 1380 112 1288 244.5 2780 534 1018.33333 165.166667
Stat3 522 0 852.5 206.5 307.5 425 558 37 775.5 184 1123 268 689.75 186.75
U-test 1.4 -06*
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Supplementary Table VII
Phosphorylation levels in anti-IL-10 treated Crohn's disease explants
CD1 CD2 CD3
IgG otelix otelix +anti-IL10 otelix + isotype IgG otelix otelix +anti-IL10 otelix + isotype IgG otelix otelix +anti-IL10 otelix + isotype
EGFR/ErbB1 869.5 542 1490.5 44.5 1118.5 243 1029 564 1070.5 278.5 858.5 115
HER2/ErbB2 790.5 215 1056.5 0 820.5 74.5 885.5 284.5 883.5 300 582 33.5
HER3/ErbB3 1050.5 411.5 1310 373.5 1153 594.5 1486.5 795 1677 830 984 119.5
FGFR1 1115.5 566.5 1436.5 177.5 1281 831 1324 749 1483 426.5 1236 115
FGFR3 663.5 137.5 867 0 707.5 145.5 731 227.5 820 32.5 592 0
FGFR4 514.5 95.5 833 0 620 7.5 707.5 3 634 108 532.5 0
InsR 601 11 848.5 0 690 0 581 0 722.5 176 235 0
IGF-IR 694 84 916.5 17 714 0 672.5 0 775.5 362.5 312.5 0
TrkA/NTRK1 453.5 0 658 0 450 51.5 466 0 513 0 343.5 0
TrkB/NTRK2 217.5 0 510.5 0 286 0 333 0 381 0 128 0
Met/HGFR 0 0 423.5 0 240.5 0 167 0 308.5 0 38 0
Ron/MST1R 314.5 0 539.5 0 338 0 293 0 444.5 0 57.5 60.5
Ret 460.5 0 587 0 401.5 0 330 0 494 83 160 0
ALK 848.5 516 1182.5 408 1312 793 1254 123.5 1508.5 135.5 931.5 1159.5
PDGFR 206 103.5 811.5 12 486 139 377 0 767 0 184 367.5
c-kit/SCFR 0 51.5 668.5 0 258 0 68.5 0 379.5 0 0 241.5
FLT3/Flk2 1 0 662 0 224.5 0 42.5 0 322 0 0 191.5
M-CSFR/CSF-1R 121 0 586.5 0 87.5 0 0 0 264 31 0 242.5
EphA1 0 0 595 0 188.5 159 112.5 0 523.5 0 404 147.5
EphA2 0 0 502.5 0 225.5 53 0 0 480.5 0 170.5 226
EphA3 0 0 338 0 11.5 0 0 0 84 0 133.5 209
EphB1 0 0 315.5 0 17.5 0 0 0 0 0 0 233.5
EphB3 0 0 447 0 0 0 0 0 247 0 178.5 263
EphB4 0 0 302.5 0 0 0 0 0 0 0 160 0
Tyro3/Dtk 0 0 115.5 0 0 0 0 0 0 0 0 0
Axl 0 0 140 0 0 0 0 0 0 0 0 0
Tie2/TEK 0 0 192.5 0 0 0 0 0 85.5 0 124.5 41.5
VEGFR2/KDR 0 0 132.5 0 0 0 0 0 26.5 0 0 12
Akt/PKB/Rac Thr308 460 0 795 302 527 6 454.5 59.5 446.5 0 828 0
Akt/PKB/Rac Ser473 778 0 697.5 236 1083 67.5 772 339 965 0 1474 5
p44/42 MAPK (ERK1/2) 18 0 376 39 319.5 0 143.5 0 207 0 105.5 0
S6 ribos. Protein 256 0 330 144 454.5 0 304.5 0 508 0 951.5 31.5
c-Abl 0 0 209.5 100 14 0 86 0 128.5 0 72.5 12.5
IRS-1 811.5 202.5 1187.5 702.5 611 210 889 364.5 669.5 0 251 88.5
Zap-70 783 449 1262 658.5 800 465 914 416 739.5 0 245.5 31.5
Src 792.5 392 949.5 626.5 760 176.5 814 254 690.5 0 127.5 0
Lck 758 598.5 852 628 646 115 691.5 72.5 561 0 140 0
Stat1 747.5 748 962 740.5 890 138 800.5 124 624.5 0 356.5 67.5
Stat3 893.5 864 1501 1047 1210 514 1410 899.5 1207 19.5 318 0
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CD4 CD5 AVERAGE
IgG otelix otelix +anti-IL10 otelix + isotype IgG otelix otelix +anti-IL10 otelix + isotype otelix +anti-IL10 otelix + isotype
EGFR/ErbB1 753.5 439 1292.5 38.5 1140 247 1049.5 575.5 1144 267.5
HER2/ErbB2 685.5 174 915.5 0 836 75 903 290 868.5 121.6
HER3/ErbB3 910.5 333.5 1135 323.5 1176 606 1516 810 1286.3 484.3
FGFR1 967 458 1245.5 153.5 1306 847 1350 763 1318.4 391.6
FGFR3 575 111.5 751 0 721 148 745 232.5 737.2 92
FGFR4 446 77.5 722 0 632 7.5 721.5 3 703.3 1.2
InsR 521 8 735.5 0 703 0 592 0 598.4 0
IGF-IR 601 68 794.5 14 728 0 685.5 0 676.3 6.2
TrkA/NTRK1 393 0 570 0 459 52.5 475 0 502.5 0
TrkB/NTRK2 188 0 442.5 0 291 0 339 103 350.6 20.6
Met/HGFR 0 0 367.5 0 245 0 170 0 233.2 0
Ron/MST1R 272 0 467 0 344.5 0 298 54 331 22.9
Ret 399 0 508 0 409.5 0 336 0 384.2 0
ALK 735 417 1025.5 353 1338 808 1279 125 1134.5 433.8
PDGFR 178 83.5 703 10 495 141 384.5 0 492 77.9
c-kit/SCFR 0 41.5 579 0 263 0 69 0 277 48.3
FLT3/Flk2 346 0 573 0 228 0 43.5 0 264.2 38.3
M-CSFR/CSF-1R 104 0 508.5 0 89.5 0 0 0 219 48.5
EphA1 0 0 515 22 192 162 114.5 0 348.2 33.9
EphA2 0 0 435.5 0 230 54 0 22 221.7 49.6
EphA3 0 0 293 0 11 0 0 0 152.9 41.8
EphB1 144 0 273 0 17.5 0 0 0 117.7 46.7
EphB3 0 0 387 0 0 0 0 0 202.5 52.6
EphB4 0 0 262.5 0 0 0 0 0 145 0
Tyro3/Dtk 0 0 100.5 0 36 0 49.5 0 53.1 0
Axl 0 0 121 0 0 0 0 0 52.2 0
Tie2/TEK 0 0 166.5 0 0 0 0 0 96.7 8.3
VEGFR2/KDR 0 0 114.5 0 0 0 0 0 49.4 2.4
Akt/PKB/Rac Thr308 398 0 689 261 537.5 6.5 463 60 645.9 136.5
Akt/PKB/Rac Ser473 674 0 604 204 1104 68.5 787 345 866.9 225.8
p44/42 MAPK (ERK1/2) 15 0 325 33 325 0 146 0 219.2 14.4
S6 ribos. Protein 221 0 286 124 463.5 0 310.5 0 436.5 59.9
c-Abl 0 0 181 86 14 0 87 0 127.2 39.7
IRS-1 703 164.5 1029.5 609 623 214 906 371 852.6 427.1
Zap-70 678 363 1094 570.5 816 474 932.5 424 889.6 420.1
Src 687.5 317.5 823.5 543.5 775 180 830 259 708.9 336.6
Lck 657 484.5 738 544 658 117 705 73.5 625.3 263.6
Stat1 648.5 605 834 642 907 140 816 126 753.8 340
Stat3 774.5 699 1301 907 1234 524 1438 917 1193.6 754.1
U-test 6.61144e-08*
